You know this trial is a double-blinded control trial right? The data doesn't get unlocked prior to complete patient enrolment and after the last time-point. This extension is not a reflection of "quality data" being seen. This (as they stated), is due to feedback from KOL's that twice weekly injections isn;t commercially appetising, hence they're trying once a week. IMO
Ann: Phase 2 Synovial Fluid Biomarker Study Update, page-49
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.5¢ |
Change
0.025(10.9%) |
Mkt cap ! $87.44M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 28.0¢ | 24.0¢ | $288.4K | 1.157M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 32617 | 25.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 52942 | 3 |
View Market Depth
| Last trade - 14.13pm 20/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |